Institution
Bascom Palmer Eye Institute
About: Bascom Palmer Eye Institute is a based out in . It is known for research contribution in the topics: Glaucoma & Visual acuity. The organization has 1668 authors who have published 2248 publications receiving 78159 citations.
Topics: Glaucoma, Visual acuity, Intraocular pressure, Retinal, Endophthalmitis
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Abstract: Background Ranibizumab — a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A — has been evaluated for the treatment of neovascular age-related macular degeneration. Methods In this multicenter, 2-year, double-blind, sham-controlled study, we randomly assigned patients with age-related macular degeneration with either minimally classic or occult (with no classic lesions) choroidal neovascularization to receive 24 monthly intravitreal injections of ranibizumab (either 0.3 mg or 0.5 mg) or sham injections. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. Results We enrolled 716 patients in the study. At 12 months, 94.5% of the group given 0.3 mg of ranibizumab and 94.6% of those given 0.5 mg lost fewer than 15 letters, as compared with 62.2% of patients receiving sham injections (P<0.001 for both comparisons). Visual acuity improved by 15 or more letters in 24.8% of the 0.3-mg group and 33.8% of the 0.5-mg group, as compared with 5.0% of the sham-injection group (P<0.001 for both doses). Mean increases in visual acuity were 6.5 letters in the 0.3-mg group and 7.2 letters in the 0.5-mg group, as compared with a decrease of 10.4 letters in the sham-injection group (P<0.001 for both comparisons). The benefit in visual acuity was maintained at 24 months. During 24 months, presumed endophthalmitis was identified in five patients (1.0%) and serious uveitis in six patients (1.3%) given ranibizumab. Conclusions Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration. (ClinicalTrials.gov number, NCT00056836.)
5,004 citations
••
TL;DR: Intravitreal triamcinolone is a promising therapeutic method for diabetic macular edema that fails to respond to conventional laser photocoagulation and complications do not appear to be prohibitive.
1,005 citations
••
Anglia Ruskin University1, University of Oxford2, Baylor College of Medicine3, Massachusetts Eye and Ear Infirmary4, University of Illinois at Chicago5, Charité6, University of New South Wales7, Keio University8, Bascom Palmer Eye Institute9, Kyoto Prefectural University of Medicine10, Tufts University11
TL;DR: The TFOS DEWS II Pathophysiology Subcommittee reviewed the mechanisms involved in the initiation and perpetuation of dry eye disease, finding the targeting of the terminal duct in meibomian gland disease and the influence of gaze dynamics and the closed eye state on tear stability and ocular surface inflammation to be important.
Abstract: The TFOS DEWS II Pathophysiology Subcommittee reviewed the mechanisms involved in the initiation and perpetuation of dry eye disease. Its central mechanism is evaporative water loss leading to hyperosmolar tissue damage. Research in human disease and in animal models has shown that this, either directly or by inducing inflammation, causes a loss of both epithelial and goblet cells. The consequent decrease in surface wettability leads to early tear film breakup and amplifies hyperosmolarity via a Vicious Circle. Pain in dry eye is caused by tear hyperosmolarity, loss of lubrication, inflammatory mediators and neurosensory factors, while visual symptoms arise from tear and ocular surface irregularity. Increased friction targets damage to the lids and ocular surface, resulting in characteristic punctate epithelial keratitis, superior limbic keratoconjunctivitis, filamentary keratitis, lid parallel conjunctival folds, and lid wiper epitheliopathy. Hybrid dry eye disease, with features of both aqueous deficiency and increased evaporation, is common and efforts should be made to determine the relative contribution of each form to the total picture. To this end, practical methods are needed to measure tear evaporation in the clinic, and similarly, methods are needed to measure osmolarity at the tissue level across the ocular surface, to better determine the severity of dry eye. Areas for future research include the role of genetic mechanisms in non-Sjogren syndrome dry eye, the targeting of the terminal duct in meibomian gland disease and the influence of gaze dynamics and the closed eye state on tear stability and ocular surface inflammation.
994 citations
••
TL;DR: The results suggest that hESC-derived cells could provide a potentially safe new source of cells for the treatment of various unmet medical disorders requiring tissue repair or replacement.
990 citations
••
TL;DR: Tube shunt surgery had a higher success rate compared to trabeculectomy with MMC during 5 years of follow-up in the TVT Study and both procedures were associated with similar IOP reduction and use of supplemental medical therapy at 5 years.
829 citations
Authors
Showing all 1668 results
Name | H-index | Papers | Citations |
---|---|---|---|
Samuel G. Jacobson | 101 | 416 | 32653 |
Jonathan L. Haines | 100 | 463 | 40225 |
Scheffer C.G. Tseng | 93 | 333 | 29213 |
Carmen A. Puliafito | 90 | 317 | 53411 |
Harry W. Flynn | 83 | 709 | 26642 |
Artur V. Cideciyan | 82 | 275 | 20805 |
William J. Feuer | 80 | 403 | 21870 |
Ingrid U. Scott | 79 | 524 | 22220 |
Philip J. Rosenfeld | 77 | 325 | 28506 |
Ashish Sharma | 75 | 909 | 20460 |
William E. Smiddy | 66 | 357 | 12745 |
Gary W. Abrams | 65 | 286 | 13202 |
Ronald N. Goldberg | 63 | 222 | 20247 |
Mark S. Blumenkranz | 61 | 261 | 14385 |
J. William Harbour | 60 | 214 | 13438 |